Pharmacokinetic/pharmacodynamic modeling: What it is!
Tóm tắt
Although Pharmacokinetic/pharmacodynamic modeling has been around for decades, it is still in its infancy with respect to the future of its current manifestation. Due to the amount of time and other resources that must be committed for successful development and application of these methods, economic incentives must be made available to academic and industrial scientists through the NIH and FDA, respectively. The long-term returns should more than compensate for the investments in the form of scientific understanding of the concentration-effect relationships as well as more efficient and acceptable NDAs. Could this be the answer to the drug lag in the United States and other countries?
Tài liệu tham khảo
T. R. Norman and G. D. Burrows. Plasma concentrations of benzodiazepines—A review of clinical findings and implications.Prog. Neuropsychopharmacol. Biol. Psychiat. 8:115–126 (1984).
R. O. Friedel. Relationships of plasma levels of benzodiazepines and clinical response: A critical review. In E. Usdin (ed.),Clinical Pharmacology in Psychiatry, Elsevier, North Holland, Inc., New York, 1981.
C. Bellantuono, V. Reggi, G. Tognoni, and S. Garattini. Benzodiazepines: Clinical pharmacology and therapeutic use.Drugs 19:195–219 (1980).
T. M. Itil and K. Z. Itil. The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping.J. Clin. Psychiat. 47:(9-Suppl):20–27 (1986).
R. Nagashima, R. A. O'Reilly, and G. Levy. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin.Clin. Pharmacol. Ther. 10:22–35 (1969).
G. Levy, M. Gibaldi, and W. Jusko. Multicompartment pharmacokinetic models and pharmacologie effects.J. Pharm. Sci. 58:422–424 (1969).
L. K. Paalzow. Integrated pharmacokinetic-dynamic modeling of drugs acting on the CNS.Drug Metab. Rev. 15:383–400 (1984).
M. Gibaldi and D. Perrier.Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982, pp. 355–384.
J. G. Wagner. Kinetics of pharmacologic response. I: Proposed relationships between response and drug concentration in the intact animal and man.J. Theor. biol. 20:173–201 (1968).
G. Segre. Kinetics of interaction between drugs and biological systems.Il Farmaco 23:907–918 (1968).
C. J. Hull, H. B. H. V. Beem, K. McLeod, A. Sibbald, and M. J. Watson. A pharmacodynamic model for pancuronium.Brit. J. Anaesth. 50:1113–1123 (1978).
L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.Clin. Pharmacol. Ther. 25:358–370 (1979).
W. A. Colburn and M. L. Jack. Relationships among CSF drug concentrations, receptor binding characteristics, and pharmacokinetic and pharmacodynamic properties of selected 1,4-substituted benzodiazepines.Clin. Pharmacokin. 13:179–190 (1987).
W. A. Colburn. Simultaneous pharmacokinetic and pharmacodynamic modeling.J. Pharmacokin. Biopharm. 9:367–388 (1981).
W. A. Colburn and R. K. Brazzell. Pharmacokinetics as an aid to understanding drug effects. In K. M. Foley and C. E. Inturrisi (eds.),Advances in Pain Research and Therapy, Vol. 8, Raven Press, New York, 1986, pp. 427–439.
W. A. Colburn. Pharmacokinetic/Pharmacodynamic Modeling: Study Design Considerations. In R. B. Smith, P. O. Kroboth, and R. P. Juhl (eds.),Pharmacokinetics and Pharmacodynamics, Research Design and Analysis, Harvey Whitney Books, Cincinnati, OH, 1986, chap. 6, pp. 65–84.
W. A. Colburn. Pharmacokinetics/pharmacodynamics: Measures, models and manipulations. In J. Young, V. W. Ingalls, and R. Hawkins (eds.), Simulation at the Frontiers of Science, Society for Computer Simulation, San Diego, CA, 1986, pp. 7–11.
E. Fuseau and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.Clin. Pharmacol Ther,35:733–741 (1984).
J. D. Unadkat, F. Bartha, and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.Clin. Pharmacol. Ther. 40:86–93 (1986).
A. Wellstein, D. Palm, H. F. Pitschner, and G. G. Belz. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.Eur. J. Clin. Pharmacol. 29:131–147 (1985).
D. M. Gibson, M. E. Taylor, and W. A. Colburn. Curve-fitting and unique parameter identification.J. Pharm. Sci. (in press).